ea0038p108 | Clinical practice/governance and case reports | SFEBES2015
Anstey Julia
, Solomon Andrew
, Nathan Paul
, Shaw Heather
Ipilimumab, pembrolizumab, and nivolumab novel immune checkpoint blockade drugs are increasingly used in the treatment of metastatic melanoma and other cancers. Ipilimumab is an anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) MAB and the first drug shown to improve overall survival in metastatic melanoma. Hypophysitis is a widely described side-effect linked with both lymphocytic inflammation and a direct toxic effect on the pituitary in mouse studies, but has been...